CoChat

Phase 2b, randomized, double‐blind 12‐week studies of TZP ‐102, a ghrelin receptor agonist for diabetic gastroparesis

McCallum, R. W., Lembo, A., Esfandyari, T., Bhandari, B. R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J., Rousseau, F., The TZP‐102 Phase 2b Study Group · 2013 · Neurogastroenterology & Motility
Cited by 101

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: TZP ‐102, a potent, oral, ghrelin receptor agonist, improved diabetic gastroparesis symptoms in Phase 2a. Methods: Patients with type 1 or 2 diabetes, delayed gastric half‐emptying (T 1/2 ), and ≥3 months gastroparesis symptoms randomized 1 : 1 : 1 to double‐blind placebo, 10‐mg, or 20‐mg TZP ‐102 once daily for 12 weeks (Study TZP ‐102‐ CL ‐G003). Study TZP ‐102‐ CL ‐G004 patients randomized 1 : 1 to 10‐mg TZP ‐102:placebo three‐times‐daily. Primary endpoint was change‐from‐baseline through Weeks 11–12 in Daily Diary of Gastroparesis Symptoms Questionnaire ( GSDD ) via electronic Patient Recorded Outcome device: worst severity of nausea, early satiety, bloating, and upper abdominal pain in 24 h (0 = none‐to‐5 = very severe). GSDD Composite Score for eligibility was ≥2.5 (Day‐14‐to‐baseline). Patient Overall Treatment Evaluation ( OTE ) provided an anchor‐based minimal clinically important difference ( MCID ) for GSDD Composite Score. Key Results: Study TZP ‐102‐ CL ‐G003 enrolled 201 outpatients: females 72%; Caucasians 87%; type 2 diabetes 61%; insulin‐dependent 65%; age mean ± SD 53 ± 11.3 years; HbA1c 7.8 ± 1.5%; GCSI 3.4 ± 0.7; GSDD Composite 3.6 ± 0.6; gastric T 1/2 131 ± 32 min; n = 69 (10‐mg), n = 66 (20‐mg), n = 66 (placebo). Primary endpoint ( GSDD ): significant improvement in all arms, although not for TZP ‐102 vs placebo: mean change‐from‐baseline −1.7, −1.4, −1.5 (10‐mg, 20‐mg, placebo); Gastroparesis Cardinal Symptom Index −1.8, −1.6, −1.5, respectively. The OTE (all patients) at Week‐12 was: Patient 3.7 ± 3.2 and Physician 3.6 ± 3.0 with median score for both of 5.0 = important on scale of improvement; individual MCID was 1.61 and 0.94 for group analyses, greater than expected. Study TZP ‐102‐ CL ‐G004 with similar demographic/disease characteristics was prematurely terminated for efficacy futility (n = 64 with Week‐4 assessments). Conclusions & Inferences: Efficacy of TZP ‐102 was not demonstrated compared with placebo in diabetic gastroparesis; however, there was substantial symptom improvement in all arms ( ClinicalTrials.gov NCT01452815/NCT01664637).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/nmo.12184

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 101

Metadata

Authors
McCallum, R. W., Lembo, A., Esfandyari, T., Bhandari, B. R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J., Rousseau, F., & The TZP‐102 Phase 2b Study Group
Venue
Neurogastroenterology & Motility
Publisher
Wiley
Published
2013-07-15
Volume
25
Issue
11
Pages
e705-17
ISSN
  • 1350-1925 (ISSN-L)
  • 1365-2982
OpenAlex
W2087955556
Cited by
101
References
10
FWCI
13.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2b, randomized, double‐blind 12‐week studies of TZP ‐102, a ghrelin receptor agonist for diabetic gastroparesis. https://app.cochat.ai/papers/10.1111/nmo.12184
The paper
McCallum, R. W., Lembo, A., Esfandyari, T., Bhandari, B. R., Ejskjaer, N., Cosentino, C., Helton, N., Mondou, E., Quinn, J., Rousseau, F., & The TZP‐102 Phase 2b Study Group. (2013). Phase 2b, randomized, double‐blind 12‐week studies of TZP ‐102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.12184

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.